Update on antimicrobial agents: New indications of older agents

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 10, 2005, Pages 1681-1691

  Pasquale, Timothy R ^a   Tan, James S ^a  

^a SUMMA HEALTH SYSTEM   (United States)

Author keywords

Acinetobacter spp.; Aminoglycosides; Ampicillin; Clindamycin; Colistin; Cystic fibrosis; Doxycycline; Fluoroquinolones; Macrolides; Minocylcine; Mycobacteria; Plasmodium falciparum; Staphylococcus aureus; Sulbactam; Sulfamethoxazole; Trimethoprim; Wegener's Granulomatosis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; ATOVAQUONE; AZITHROMYCIN; CEFTRIAXONE; CHLOROQUINE; CLARITHROMYCIN; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; LINEZOLID; MACROLIDE; METICILLIN; METRONIDAZOLE; MINOCYCLINE; PENICILLIN G; PLACEBO; PROTON PUMP INHIBITOR; PYRIMETHAMINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER; ANTHRAX; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ATYPICAL MYCOBACTERIUM; BABESIA; BABESIOSIS; BACILLUS ANTHRACIS; BACTERIAL INFECTION; BARTONELLA HENSELAE; BORDETELLA PERTUSSIS; BORRELIA; BRONCHIOLITIS; CAMPYLOBACTER JEJUNI; CHLAMYDOPHILA PNEUMONIAE; CHRONIC INFLAMMATION; COCCIDIA; COCCIDIOSIS; CRYPTOSPORIDIUM; CYCLOSPORA; CYCLOSPORIASIS; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG INDICATION; DRUG RESEARCH; EAR DISEASE; FRANCISELLA TULARENSIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HAEMOPHILUS DUCREYI; HELICOBACTER PYLORI; HUMAN; KIDNEY DISEASE; LEGIONELLA PNEUMOPHILA; LYME DISEASE; MALARIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEUROLOGIC DISEASE; PLASMODIUM MALARIAE; PNEUMOCYSTIS; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW; SALMONELLA TYPHI; SEXUALLY TRANSMITTED DISEASE; STREPTOCOCCUS GROUP A; SYPHILIS; TOXOPLASMA; TOXOPLASMOSIS; TREPONEMA PALLIDUM; TULAREMIA; UREAPLASMA UREALYTICUM; WEGENER GRANULOMATOSIS;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MICROBIAL; HUMANS; INFLAMMATION; MYCOSES;

EID: 23844477661     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.10.1681     Document Type: Review

References (99)

1. GORDON KA, BIEDENBACH DJ, JONES RN: Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. (2003) 46(4):285-289.
2. ALTUNAIJI S, KUKURUZOVIC R, CURTIS N, MASSIE J: Antibiotics for whooping cough (pertussis). Cochrane Database Syst. Rev. (2005) (1):CD004404.
3. FRENCH AL, BENATOR DA, GORDIN FM: Nontuberculous mycobacterial infections. Med. Clin. North Am. (1997) 81(2):361-379.
4. LUFT BJ, DATTWYLER RJ, JOHNSON RC et al.: Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized, controlled trial. Ann. Intern. Med. (1996) 124(9):785-791.
5. STRLE F, MARASPIN V, LOTRIC-FURLAN S, RUZIC-SABLJIC E, CIMPERMAN J: Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. Infection (1996) 24(1):64-68.
6. BARSIC B, MARETIC T, MAJERUS L, STRUGAR J: Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection (2000) 28(3):153-156.
7. HOOK EW 3RD, STEPHENS J, ENNIS DM: Azithromycin compared with penicillin G benzathine for treatment of incubating syphilis. Ann. Intern. Med. (1999) 131(6):434-437.
8. VERDON MS, HANDSFIELD HH, JOHNSON RB: Pilot study of azithromycin for treatment of primary and secondary syphilis. Clin. Infect. Dis. (1994) 19(3):486-488.
9. MASHKILLEYSON AL, GOMBERG MA, MASHKILLEYSON N, KUTIN SA: Treatment of syphilis with azithromycin. Int. J. STD AIDS (1996) 7(Suppl.1):13-15.
10. O'FARRELL N: Donovanosis. Sex. Transm. Infect. (2002) 78(6):452-457.
11. AREVALO MORLES C, HERNANDEZ I, FERREIRO MC: Donovanosis: treatment with azithromycin. Int. J. STD AIDS (1997) 8(1):54-56.
12. MARTIN DH, SARGENT SJ, WENDEL GD Jr et al.: Comparison of azithromycin and ceftriaxone for the treatment of chancroid. Clin. Infect. Dis. (1995) 21(2):409-414.
13. LAHEIJ RJ, ROSSUM LG, JANSEN JB, STRAATMAN H, VERBEEK AL: Evaluation of treatment regimens to cure Helicobacter pylori infection-a meta-analysis. Aliment Pharmacol. Ther. (1999) 13(7):857-864.
14. WALSH JH, PETERSON WL: Drug therapy: the treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N. Engl. J. Med. (1995) 333:984-991.
15. LACASSIN F, SCHAFFO D, PERRONNE C, LONGUET P, LEPORT C, VILDE JL: Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. (1995) 39(1):276-277.
16. CONRAD DA. Treatment of cat-scratch disease. Curr. Opin. Pediatr. (2001) 13(1):56-59.
17. IVES TJ, MANZEWITSCH P, REGNERY RL, BUTTS JD, KEBEDE M: In vitro susceptibilities of Bartonella henselae, B. quiniana, B. elizabethae, Rickettsia ricketsii, R. conorii, R. akari, and R. prowazekii to macrolide antibiotics as determined by immunofluorescent-antibody analysis of infected Vero cell monolayers. Antimicrob. Agents Chemother. (1997) 41(3):578-582.
18. WEISS LM: Babesiosis in humans: a treatment review. Expert Opin. Pharmacother. (2002) 3(8):1109-1115.
19. KRAUSE PJ: Babesiosis diagnosis and treatment. Vector Borne Zoonotic Dis. (2003) 3(1):45-51.
20. KRAUSE PJ, LEPORE T, SIKAND VK et al.: Atovaquone and azithromycin for the treatment of babesiosis. N. Engl. J. Med. (2000) 343:1454-1458.
21. TAYLOR WR, RICHIE TL, FRYAUFF DJ et al.: Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin. Infect. Dis. (1999) 28(1):74-81.
22. ANDERSON SL, BERMAN J, KUSCHNER R et al.: Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Ann. Intern. Med. (1995) 123(10):771-773.
23. DUNNE MW, BOZZETTE S, MCCUTCHAN JA et al.: Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group. Lancet (1999) 354(9182):891-895.
24. HUGHES WT, DANKNER WM, YOGEV R et al.: Comparison of arovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Clin. Infect. Dis. (2005) 40(1):136-145.
25. PASQUALE TR, TAN JS: Nonantimicrobial effects of antibacterial agents. Clin. Infect. Dis. (2005) 40(1):127-135.
26. GOTFRIED MH: Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest (2004) 125(2 Suppl.):52S-60S.
27. KUDOH S: Erythromycin treatment in diffuse panbronchiolitis. Curr. Opin. Pulm. Med. (1998) 4(2):116-121.
28. RUBIN BK, HENKE MO: Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest (2004) 125(2 Suppl.):70S-78S.
29. SAIMAN L, MARSHALL BC, MAYER-HAMBLETT N et al.: Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA (2003) 290(13):1749-1756.
30. PARNHAM MJ: Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr. Opin. Infect. Dis. (2005) 18(2):125-131.
31. TAMAOKI J, TAKEYAMA K, TAGAYA E, KONNO K: Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob. Agents Chemother. (1995) 39(8):1688-1690.
32. WORMSER GP, NADELMAN RB, DATTWYLER RJ et al.: Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 31(Suppl. 1): 1-14.
33. YOUNG EJ: Brucella speciea (Brucellosis). In: Antimicrobial therapy and vaccines Volume I. Microbes. VL Yu, R Weber, D Raoult (Eds), Appletree Publications, LLC, New York, NY, USA (2002) 121-40.
34. DERESINSKI S: Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis. (2005) 40(4):562-573.
35. Vancomycin-resistant Staphylococcus aureus-Pennsylvania. MMWR Morb. Mortal. Wkly. Rep. (2002) 51(40):902.
36. ADRA M, LAWRENCE KR: Trimethoprim/suffamethoxazole for treatment of severe Staphylococcus aureus infections. Ann. Pharmacother. (2004) 38(2):338-341.
37. RECOMMENDATIONS FOR PREVENTING THE SPREAD OF VANCOMYCIN RESISTANCE: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm. Rep. (1995) 44(RR-12):1-13.
38. DIEKEMA DJ, PFALLER MA, SCHMITZ FJ et al.: Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. (2001) 32(Suppl.2):S114-S132.
39. SCHMITZ FJ, KREY A, SADURSKI R, VERHOEF J, MILATOVIC D, FLUIT AC: Resistance to tetracycline and distribution of tetracycline resistance genes in European Staphylococcus aureus isolates. J. Antimicrob. Chemother. (2001) 47(2):239-240.
40. LAWLOR MT, SULLIVAN MC, LEVITZ RE, QUINTILIANI R, NIGHTINGALE C: Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline. J. Infect. Dis. (1990) 161(4):812-814.
41. NICOLAU DP, FREEMAN CD, NIGHTINGALE CH, COE CJ, QUINTILLANI R: Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (1994) 38(7):1515-1518.
42. RUHE J: Use of tetracyclines for infections caused by methicillin-resistant Staphylococcus aureus. In Program and Abstracts of the 42nd Annual Meeting of the Infectious Disease Society America. Boston, MA, USA (2004) Abstract 516.
43. JONG EC, NOTHDURFT HD: Current drugs for antimalarial chemoprophylaxis: a review of efficacy and safety. J. Travel Med. (2001) 8(Suppl. 3):S48-S56.
44. PANG LW, LIMSOMWONG N, BOUDREAU EF, SINGHARAJ P: Doxycycline prophylaxis for falciparum malaria. Lancet (1987) 1(8543):1161-1164.
45. LOBEL HO, KOZARSKY PE: Update on prevention of malaria for travelers. JAMA (1997) 278(21):1767-1771.
46. CENTERS FOR DISEASE CONTROL AND PREVENTION: Health Information for International Travel 2003-2004. Altanta: US Department of Health and Human Services, Public Health Service (2003).
47. RAWAL SY, RAWAL YB: Non-antimicrobial properties of tetracyclines-dental and medical implications. West Indian Med. J. (2001) 50(2):105-108.
48. GOLUB LM, RAMAMURTHY NS, MCNAMARA TF, GREENWALD RA, RIFKIN BR: Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit. Rev. Oral Biol. Med. (1991) 2(3):297-321.
49. DUIVENVOORDEN WC, POPOVIC SV, LHOTAK S et al.: Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer Res. (2002) 62(6):1588-1591.
50. JOHN A, TUSZYNSKI G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol. Oncol. Res. (2001) 7(1):14-23.
51. SAIKALI Z, SINGH G: Doxycycline and other tetracyclines in the treatment of bone metastasis. Anticancer Drugs (2003) 14(10):773-778.
52. SHAPIRA L, SOSKOLNE WA, HOURI Y, BARAK V, HALABI A, STABHOLZ A. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cyrokine secretion. Infect. Immun. (1996) 64(3):825-828.
53. TENG YD, CHOI H, ONARIO RC et al.: Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc. Natl. Acad. Sci. USA (2004) 101(9):3071-3076.
54. FAGAN SC, EDWARDS DJ, BORLONGAN CV et al.: Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection. Exp. Neurol. (2004) 186(2):248-251.
55. WELLS JE, HURLBERT RJ, FEHLINGS MG, YONG VW: Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain (2003) 126(Pt 7):1628-1637.
56. YONG VW. Prospects for neuroprotection in multiple sclerosis. Front Biosci. (2004) 9:864-872.
57. MARKOWITZ N, QUINN EL, SARAVOLATZ LD: Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann. Intern. Med. (1992) 117(5):390-398.
58. GODMAN GC, CHURG J: Wegener's granutomatosis: pathology and review of the literature. AMA Arch. Pathol. (1954) 58(6):533-553.
59. FAUCI AS, HAYNES BF, KATZ P, WOLFF SM: Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann. Intern. Med. (1983) 98(1):76-85.
60. TERVAERT JW, VAN DER WOUDE FJ, FAUCI AS et al.: Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch. Intern. Med. (1989) 149(11):2461-2465.
61. STEGEMAN CA, TERVAERT JW. SLUITER WJ, MANSON WL, DE JONG PE, KALLENBERG CG: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann. Intern. Med. (1994) 120(1):12-17.
62. VAN DER WOUDE FJ, RASMUSSEN N, LOBATTO S et al.: Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet (1985) 1(8426):425-429.
63. TERVAERT JW, HUITEMA MG, HENE RJ et al.: Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet (1990) 336(8717):709-711.
64. PINCHING AJ, REES AJ, PUSSELL BA, LOCKWOOD CM, MITCHISON RS, PETERS DK: Relapses in Wegener's granulomatosis: the role of infection. Br. Med. J. (1980) 281(6244):836-838.
65. REINHOLD-KELLER E, DE GROOT K, RUDERT H, NOLLE B, HELLER M, GROSS WL: Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. Qjm (1996) 89(1):15-23.
66. STEGEMAN CA, TERVAERT JW, DE JONG PE, KALLENBERG CC: Trimethoprim-sulfamethoxazole (cotrimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N. Engl. J. Med. (1996) 335(1):16-20.
67. REGAN MJ, HELLMANN DB, STONE JH: Treatment of Wegener's granulomatosis. Rheum. Dis. Clin. North Am. (2001) 27(4):863-886.
68. MANSFIELD LS, GAJADHAR AA: Cyclospora cayetanensis, a food- and waterborne coccidian parasite. Vet. Parasitol. (2004) 126(1-2):73-90.
69. HERWALDT BL: Cyclospora cayetanensis: a review, focusing on the outbreaks of cyclosporiasis in the 1990s. Clin. Infect. Dis. (2000) 31(4):1040-1057.
70. HOGE CW, SHLIM DR, GHIMIRE M et al.: Placebo-controlled trial of cotrimoxazole for Cyclospora infections among travellers and foreign residents in Nepal. Lancet (1995) 345(8951):691-693.
71. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. (2005) 171(4):388-416.
72. GALES AC, JONES RN, FORWARD KR, LINARES J, SADER HS, VERHOEF J: Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin. Infect. Dis. (2001) 32(Suppl. 2):S104-S113.
73. WOOD GC, HANES SD, CROCE MA, FABIAN TC, BOUCHER BA: Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. Clin. Infect. Dis. (2002) 34(11):1425-1430.
74. LEVIN AS, LEVY CE, MANRIQUE AE, MEDEIROS EA, COSTA SF: Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int. J. Antimicrob. Agents (2003) 21(1):58-62.
75. SMOLYAKOV R, BORER A, RIESENBERG K et al.: Nosocomial multidrug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J. Hosp. Infect. (2003) 54(1):32-38.
76. JAIN R, DANZIGER LH: Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann. Pharmacother. (2004) 38(9):1449-1459.
77. WELSH MJ, TSUI L, BOAT T. BEAUDEN A: Cystic fibrosis. In: Metabolic and molecular basis of inherited disease (7th Edition). C Scriver, A Beaudet, D Valle, (Eds), McGraw-Hill, New York, NY, USA (1995).
78. CLANCY JP, BEBOK Z, RUIZ F et al.: Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. (2001) 163(7):1683-1692.
79. HOWARD M, FRIZZELL RA, BEDWELL DM: Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med. (1996) 2(4):467-469.
80. KEREM E: Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr. Opin. Pulm. Med. (2004) 10(6):547-552.
81. WILSCHANSKI M, YAHAV Y, YAACOV Y et al.: Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. (2003) 349(15):1433-1441.
82. LEWIS C: Antiplasmodial activity of 7-halogenated lincomycins. J. Parasitol. (1968) 54(1):169-170.
83. LEWIS C: Antiplasmodial activity of halogenated lincomycin analogues in Plasmodium berghei-infected mice. Antimicrob. Agents Chemother. (1967) 7:537-542.
84. CLYDE DF, GILMAN RH, MCCARTHY VC: Antimalarial effects of clindamycin in man. Am. J. Trop. Med. Hyg. (1975) 24(2):369-370.
85. LELL B, KREMSNER PC: Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob. Agents Chemother. (2002) 46(8):2315-2320.
86. KREMSNER PG, ZOTTER CM, GRANINGER W, ROCHA RM, BIENZLE U, FELDMEIER H: Clindamycin is effective against Plasmodium falciparum but not against P. vivax in mixed infections. Trans. R. Soc. Trop. Med. Hyg. (1989) 83(3):332-333.
87. GINSBURG AS, GROSSET JH, BISHAI WR: Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. (2003) 3(7):432-442.
88. VON ROSENSTIEL N, ADAM D: Quinolone antibacterials. An update of their pharmacology and therapeutic use. Drugs (1994) 47(6):872-901.
89. BRYSKIER A, LOWTHER J: Fluoroquinolones and tuberculosis. Expert Opin. Investig. Drugs (2002) 11(2):233-258.
90. ALANGADEN GJ, LERNER SA: The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin. Infect. Dis. (1997) 25(5):1213-1221.
91. BLUMBERG HM, BURMAN WJ, CHAISSON RE et al.: American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. (2003) 167(4):603-662.
92. JI B, LOUNIS N, MASLO C, TRUFFOT-PERNOT C, BONNAFOUS P, GROSSET J: In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (1998) 42(8):2066-2069.
93. BERNING SE: The role of fluoroquinolones in tuberculosis today. Drugs (2001) 61(1):9-18.
94. Treatment of tuberculosis. MMWR Recomm. Rep. (2003) 52(RR-11):1-77.
95. LI J, NATION RL, MILNE RW, TURNIDGE JD, COULTHARD K: Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents (2005) 25(1):11-25.
96. LIVERMORE DM: Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. (2002) 34(5):634-640.
97. LEVIN AS, BARONE AA, PENCO J et al.: Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. (1999) 28(5):1008-1011.
98. LINDEN PK, KUSNE S, COLEY K, FONTES P, KRAMER DJ, PATERSON D: Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin. Infect. Dis. (2003) 37(11):e154-e160.
99. MARKOU N, APOSTOLAKOS H, KOUMOUDIOU C et al.: Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit. Care (2003) 7(5):R78-R83.